Stock Markets June 25, 2026 02:18 PM

Denali Therapeutics Sees Surge in Options Activity, Volatility Spikes

Options volume climbs to 2,291 contracts as calls dominate trading; implied volatility and skew rise alongside modest share gains

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
DNLI

Options trading in Denali Therapeutics Inc. rose to 2,291 contracts by 2:10 p.m. New York time on Thursday, with call activity accounting for the majority of trades. The July 17, 2026 $30 call comprised the largest single series trade, while implied volatility and the 90/110 skew both increased. Shares were modestly higher.

Denali Therapeutics Sees Surge in Options Activity, Volatility Spikes
DNLI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Options activity in Denali Therapeutics reached 2,291 contracts by 2:10 p.m. New York time, with calls making up 1,863 contracts and puts 428 contracts - impacting derivatives market liquidity and sentiment.
  • The July 17, 2026 $30 call series accounted for 1,535 contracts traded, while its open interest was recorded at 10 contracts as of Wednesday - a noteworthy concentration within the options market.
  • Implied risk measures rose: three-month implied volatility increased to 86.41% and the three-month 90/110 skew climbed to 8.53 percentage points - highlighting elevated uncertainty in the equity's near-term pricing. Sectors impacted include biotechnology equities and options/derivatives markets.

Trading in options tied to Denali Therapeutics Inc. (NASDAQ:DNLI) jumped to a total of 2,291 contracts at 2:10 p.m. New York time on Thursday, according to exchange data compiled by Bloomberg.

The activity was dominated by calls, with call volume reaching 1,863 contracts and puts totaling 428 contracts. The most heavily traded single series was the July 17, 2026 $30 call, which accounted for 1,535 contracts. That series had an open interest of 10 contracts as of Wednesday.

On the equities side, Denali Therapeutics shares traded at $24.91, up 0.36% on the session. Market-implied measures showed rising uncertainty: three-month implied volatility increased by 17.02 percentage points to reach 86.41%. The three-month 90/110 skew also moved higher, climbing by 9.74 percentage points to 8.53 percentage points.


Context and market signals

The options flow for the session was concentrated in calls relative to puts, and a single call series represented a substantial share of the total contracts exchanged. At the same time, measures of short-term implied volatility and skew both rose, indicating increased pricing of asymmetric risk in the options market.

What the reported figures show

  • Total option contracts traded: 2,291 (as of 2:10 p.m. New York time, Thursday).
  • Call volume: 1,863 contracts; Put volume: 428 contracts.
  • Largest single series: July 17, 2026 $30 call - 1,535 contracts traded; open interest was 10 contracts as of Wednesday.
  • Share price movement: +0.36%, trading at $24.91.
  • Three-month implied volatility: rose 17.02 percentage points to 86.41%.
  • Three-month 90/110 skew: rose 9.74 percentage points to 8.53 percentage points.

The facts above reflect the exchange data and the market metrics reported for the day.

Risks

  • Elevated implied volatility (three-month volatility at 86.41%) indicates heightened short-term uncertainty for Denali Therapeutics' equity and affects option pricing - relevant to both equity and derivatives traders.
  • A single option series accounted for a large share of traded contracts (July 17, 2026 $30 call: 1,535 contracts) while showing low open interest as of Wednesday (10 contracts), which reflects a concentration of session activity in one series and may signal ephemeral or concentrated positioning - relevant to options market liquidity and risk.
  • Movements in the 90/110 skew (up to 8.53 percentage points) point to changing relative demand for out-of-the-money strikes, underscoring asymmetric risk pricing in the options market and potential uncertainty for market participants in the biotechnology sector.

More from Stock Markets

Ares again restricts redemptions at $22.6 billion flagship private credit vehicle Jun 25, 2026 SpaceX to Lay Eight-Mile Gas Pipeline to Fuel Starship Launches Jun 25, 2026 SpaceX to Construct 'Starpipe' Natural Gas Line to Fuel Starship Operations Jun 25, 2026 Palantir Shares Drop to Year Low as Software Selloff and Company-Specific Pressures Weigh Jun 25, 2026 Caterpillar Rally Accelerates After AI Data-Center Power Contract, Shares Hit Record Jun 25, 2026